Results 81 to 90 of about 2,540 (169)

Research Progress of Inclisiran

Advances in Clinical Medicine, 2022
openaire   +1 more source

New hope for hyperlipidemia management: Inclisiran [PDF]

Journal of Cardiology, 2018
Dhrubajyoti Bandyopadhyay, Adrija Hajra, Kumar Ashish, Arshna Qureshi, Somedeb Ball   +4 more
openaire   +2 more sources

Effects of inclisiran therapy on metabolomic and lipoproteomic profiles in dyslipidemic patients. [PDF]

Front Pharmacol
Patrussi J, Vignoli A, Tenori L, Sorrentino A, Berteotti M, Lotti E, Crudele F, Ciarrocca Taranta G, Rogolino AA, Barbieri G, Gori AM, Marcucci R.   +11 more
europepmc   +1 more source

Comprehensive Assessment of PCSK9 Inhibitors for Lipid Management: Scientific Guidance Based on Drug Selection Recommendations for Chinese Medical Institutions

Drug Design, Development and Therapy
Jiabao Li, Siyong Huang, Xiao Hu, Jisheng Chen Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People’s Republic of ChinaCorrespondence: Jisheng Chen, Key Specialty of Clinical Pharmacy,
Li J, Huang S, Hu X, Chen J
doaj  

Inclisiran: a novel drug for the treatment of dyslipidemia

Annals of Medicine & Surgery, 2023
Abdullah Nadeem, Rabeea Tariq, Areeba Basaria   +2 more
openaire   +2 more sources

Correction to: Inclisiran: First Approval [PDF]

Drugs, 2021
openaire   +1 more source

Lipid lowering in coronary artery disease - not just statins. [PDF]

Clin Med (Lond)
Han J, Masmanian E, Wang T, Chua TP.
europepmc   +1 more source

Inclisiran: A knight in shining armor?

American Heart Journal Plus: Cardiology Research and Practice, 2022
Michael Kelly, Dave L. Dixon
openaire   +3 more sources

Real-world effectiveness and cardiovascular outcomes of PCSK9 inhibitor therapy: a prospective registry study. [PDF]

Lipids Health Dis
Kafol J, Fras Z, Novakovic M, Sperling LS, Cevc M, Krevel B, Kafol L, Kelenc A, Kepic K, Vrbinc K, Svarc M, Groselj U, Jug B.   +12 more
europepmc   +1 more source

Ezetimibe vs Inclisiran in Coronary Artery Disease and Hyperlipidemia: A Propensity-Matched Analysis. [PDF]

JACC Adv
Akbar UA, Ijaz H, Banga A, Cheshire M, Shakeel S, Jena N, Alexander T, Dani SS.   +7 more
europepmc   +1 more source